Imasco Limited – Trademark Portfolio
Entity Type: 03
Imasco Limited has 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Notable registered marks include IMASCO. The portfolio includes 1 registered trademark. Filings span 6 Nice Classification classes, led by Class 35 (Advertising & Business) and Class 34 (Smokers Articles). This trademark owner is based in Montreal.
4 Westmount Sq.
Montreal H3Z 2S8 , CA
Showing of trademarks Trademarks
Trademark Classifications
Imasco Limited's trademark portfolio spans 6 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Advertising; business management; business administration; office functions
Building materials (non-metallic); non-metallic rigid pipes for building
Insurance; financial affairs; monetary affairs; real estate affairs
Paints, varnishes, lacquers; preservatives against rust and against deterioration of wood
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Imasco Limited have?
Imasco Limited has 7 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 abandoned, 5 cancelled.
What trademark classes does Imasco Limited file in?
Imasco Limited files trademarks across 6 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 34 (Smokers Articles), Class 19 (Building Materials), Class 36 (Insurance & Financial), Class 2 (Paints). Class 35 covers advertising; business management; business administration; office functions.
What are Imasco Limited's most well-known trademarks?
Imasco Limited's registered trademark portfolio includes well-known marks such as IMASCO. These are among 1 currently registered trademark in the portfolio.
What is Imasco Limited's trademark registration success rate?
Imasco Limited has a 14% trademark registration rate, with 1 out of 7 resolved applications resulting in successful registration. Currently, 0 applications are pending review.